Erythropoietin in the treatment of chemotherapy-induced anemia: results of phase III trials
| Study . | Chemotherapy . | Eligibility . | Study arm . | n patients . | Anemia correction (% of patients) . | Transfusions (% of patients) . |
|---|---|---|---|---|---|---|
| Cascinu [18] | CDDP | Hb < 9 | Erythropoietin | 50 | 82 | 20 |
| Placebo | 49 | 3 | 58 | |||
| Henry [19] | CDDP | Hb ≤ 10.5 | Erythropoietin | 64 | 58 | 27 |
| Placebo | 61 | NR | 56 | |||
| Case [20] | no CDDP | Hb ≤ 10.5 | Erythropoietin | 81 | 40 | 29 |
| Placebo | 76 | 4 | 37 | |||
| Osterborg [21] | no CDDP | Hb < 10 | Erythropoietin | 38 | 60 | 40 |
| Control | 39 | 24 | 76 |
| Study . | Chemotherapy . | Eligibility . | Study arm . | n patients . | Anemia correction (% of patients) . | Transfusions (% of patients) . |
|---|---|---|---|---|---|---|
| Cascinu [18] | CDDP | Hb < 9 | Erythropoietin | 50 | 82 | 20 |
| Placebo | 49 | 3 | 58 | |||
| Henry [19] | CDDP | Hb ≤ 10.5 | Erythropoietin | 64 | 58 | 27 |
| Placebo | 61 | NR | 56 | |||
| Case [20] | no CDDP | Hb ≤ 10.5 | Erythropoietin | 81 | 40 | 29 |
| Placebo | 76 | 4 | 37 | |||
| Osterborg [21] | no CDDP | Hb < 10 | Erythropoietin | 38 | 60 | 40 |
| Control | 39 | 24 | 76 |
CDDP = platinum-containing regimen; no CDDP = regimen without platinum compounds; NR = not reported; Hb = hemoglobin.
Erythropoietin in the treatment of chemotherapy-induced anemia: results of phase III trials
| Study . | Chemotherapy . | Eligibility . | Study arm . | n patients . | Anemia correction (% of patients) . | Transfusions (% of patients) . |
|---|---|---|---|---|---|---|
| Cascinu [18] | CDDP | Hb < 9 | Erythropoietin | 50 | 82 | 20 |
| Placebo | 49 | 3 | 58 | |||
| Henry [19] | CDDP | Hb ≤ 10.5 | Erythropoietin | 64 | 58 | 27 |
| Placebo | 61 | NR | 56 | |||
| Case [20] | no CDDP | Hb ≤ 10.5 | Erythropoietin | 81 | 40 | 29 |
| Placebo | 76 | 4 | 37 | |||
| Osterborg [21] | no CDDP | Hb < 10 | Erythropoietin | 38 | 60 | 40 |
| Control | 39 | 24 | 76 |
| Study . | Chemotherapy . | Eligibility . | Study arm . | n patients . | Anemia correction (% of patients) . | Transfusions (% of patients) . |
|---|---|---|---|---|---|---|
| Cascinu [18] | CDDP | Hb < 9 | Erythropoietin | 50 | 82 | 20 |
| Placebo | 49 | 3 | 58 | |||
| Henry [19] | CDDP | Hb ≤ 10.5 | Erythropoietin | 64 | 58 | 27 |
| Placebo | 61 | NR | 56 | |||
| Case [20] | no CDDP | Hb ≤ 10.5 | Erythropoietin | 81 | 40 | 29 |
| Placebo | 76 | 4 | 37 | |||
| Osterborg [21] | no CDDP | Hb < 10 | Erythropoietin | 38 | 60 | 40 |
| Control | 39 | 24 | 76 |
CDDP = platinum-containing regimen; no CDDP = regimen without platinum compounds; NR = not reported; Hb = hemoglobin.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
